Recently, Guangdong Province has released a new round of volume procurement list, and a certain biological agent (mab) is on the list...
img
we are It was speculated that insulin might be the first batch of biological preparations to be collected. As a result, rituximab took the lead and became the first batch of monoclonal antibody to enter the market.
The original research of rituximab is , Roche , the famous Rituxima , originally developed by Roche's subsidiary Genentech, approved by the US FDA in 1997, approved in Europe in 1998, and officially entered in 2000 China is the first monoclonal antibody used to treat cancer. Since the launch of rituximab injection, it has contributed nearly 100 billion in sales to and Roche Pharmaceuticals .It is also called Roche's troika together with Herceptin and Anvain.
The EU patent period of Ritux has already expired in February 2013, and the US patent also expired in September 2016. According to incomplete statistics, there are about 30 kinds of rituximab in preparation for the market worldwide.
The situation of domestic rituximab
The current domestic rituximab is distributed by Roche, , Fosun and Cinda." Since Cinda was launched on May 31 this year, its market share is not very large, but the price advantage lies there, and it is currently actively expanding its team. Fosun/Fohong Henlius's Han Likang has gone to Ritual since its listing. It has been approved for all the indications of the original research and sold for 150 million yuan in 2019, the same year. Roche sold 2.355 billion yuan. In 2020, Han Likang will produce 720,000 sticks with a retail price of 1398 yuan per stick, and annual sales of about 1 billion yuan. Henlius will get 288.3 million yuan in shares and 10.4 million yuan in licensing income. In the first half of 2021, Han Likang (rituximab) received a sales net profit of 222.2 million yuan (Han Likang was sold by the Jiangsu Fosun team), and authorized license income was 5.2 million yuan. On the other hand, Ritual China has been under the impact of imitation products. In addition to Han Likang and Dubohua that are already on the market, Shenzhou Cell, Hisun Bio, Jiahe Bio, etc. are also on the way, and Tianqing, known as the price butcher, is also here. NS.
Actually, if you look carefully at this collection list, there are not only the monoclonal antibodies of biological agents, but also the exclusive products growth hormone , the "magic flu drug" oseltamivir, etc., as well as those that are not currently involved. In the blood products field, etc., is this also sending some signals?
The collection of Rituximab (Rituxan) has come,Will the PD1 /L1 with bayonet be far behind? In other words, can the centralized procurement of the whole people be far behind?
.
